Company / Return on Equity (ROE)
Barinthus Biotherapeutics plc. Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-89.5%
FY2025
5-year range
-89.5% / 2.9%
FY2022-FY2025
Trend
-58.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Barinthus Biotherapeutics plc. reports negative total equity of -89.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-89.5% in FY2025 with a 3-year CAGR of -68.6%.
Declined from 2.9% to -89.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -68.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 58.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -89.5% | -58.7% |
| FY2024 | -56.4% | -2072.4% |
| FY2023 | 2.9% | +113.7% |
| FY2022 | -20.9% | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026